Clinical Trial Update: GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a multi-target CAR-T cell therapy designed to hit multiple cancer-associated antigens, including GPC3, Mesothelin, Claudin18.2, and oth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Multi-target CAR-T cell therapy targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, EGFR

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Lung Cancer, Cancer | Phase 1 | Status: RECRUITING